ER Editor: A google search on this topic, Roche Laboratories creating a serology test to detect the presence of “covid-19” versus influenza A and B, shows that this was making news back in April; and in early May, the FDA gave approval for this test. (We say “covid-19” in quotation marks because, to our knowledge, this virus has still not been genomically identified nor identified according to Koch’s postulates, but we remain open to correction.) It has been making news once again in the last few days because of a press release by the Swiss pharma giant revealing that it’s been granted emergency use authorization.
According to this AFP piece from 3 days ago, the test was created from the contents of nasal samples – presumably taken from patients when what is called ‘covid’ was circulating in February and March, but that is just our assumption. (Coronavirus : le laboratoire Roche obtient un feu vert pour son test qui distingue grippe et Covid-19 – Roche Labs gets green light for its test distinguishing flu from covid-19) It has the advantage of producing from 384 to 1,056 results in 3 hours. It can only be run on proprietary machines, the Cobas 6800 and 8800, already present in labs and hospitals, and not on machines used for PCR testing.
We must repeat our question: what biological ‘stuff’ is being called Covid-19?
Our libre penseur (free thinker) author below notes that flu deaths – at least in France – almost disappeared from view during the 2019-2020 flu season, yielding a total of only 88 who died of it in hospital. So it will be interesting to see what flu vs. covid statistics are produced in the upcoming season. Could so-called ‘covid’ deaths dwindle to nothing as many have suspected?
Roche Creates a Test to Differentiate Covid-19 from The Flu
LE LIBRE PENSEUR
So is it to be understood that the current tests are flawed and may confuse the two RNAs of influenza and covid-19?
We now have a better understanding of why the deaths due to the 2019-2020 seasonal flu have disappeared – 88 flu deaths in total according to figures from Public Health France:
(graph translation: Description of serious flu cases admitted to emergency during the 2019-2020 season in mainland France – data up to the 11th week of 2020.)
The Swiss pharmaceutical group Roche has developed a diagnostic test to detect and distinguish Covid-19 from influenza. The test has been approved by the US Drug Agency.
The drug and diagnostics giant Roche has been given an emergency green light in the United States for the detection and differentiation of Sars-Cov-2 and influenza A and/or B virus infections from a single nasal or nasopharyngeal swab.
This test, also available in markets recognizing the European CE mark of conformity, runs on the Cobas 6800 and 8000 laboratory systems.
“With the approach of the influenza season, the availability of this test is of particular importance due to the difficulty of differentiating between the symptoms of Sars-Cov-2 and influenza virus infections,” said Thomas Schinecker, Head of Roche Diagnostics, quoted in the press release issued on Friday ….
The Liberty Beacon Project is now expanding at a near exponential rate, and for this we are grateful and excited! But we must also be practical. For 7 years we have not asked for any donations, and have built this project with our own funds as we grew. We are now experiencing ever increasing growing pains due to the large number of websites and projects we represent. So we have just installed donation buttons on our websites and ask that you consider this when you visit them. Nothing is too small. We thank you for all your support and your considerations … (TLB)
Comment Policy: As a privately owned web site, we reserve the right to remove comments that contain spam, advertising, vulgarity, threats of violence, racism, or personal/abusive attacks on other users. This also applies to trolling, the use of more than one alias, or just intentional mischief. Enforcement of this policy is at the discretion of this websites administrators. Repeat offenders may be blocked or permanently banned without prior warning.
Disclaimer: TLB websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.
Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.